Analyst firms · Raymond James · HCAT
Raymond James HCAT price target and rating history
Health Catalyst Inc (HCAT) · Technology
Raymond James rates Health Catalyst Inc (HCAT) Mkt Perform with a $40 price target, as of its latest action on May 10, 2023. It has published 3 rating actions on HCAT since August 2021, including 0 upgrades and 1 downgrade.
- Current rating
- Mkt Perform
- Price target
- $40
- Median target, all firms
- Too few
- Actions on HCAT
- 3
Raymond James price target on HCAT
Every Raymond James rating on HCAT
- May 10, 2023
- Mar 4, 2022
- Aug 10, 2021
How other firms rate HCAT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Canaccord Genuity | Hold | $1.80 | Aug 21, 2026 |
| Wells Fargo | Equal Weight | $1 | Mar 18, 2026 |
Questions about Raymond James and HCAT
- What is Raymond James's price target for HCAT?
- Raymond James's latest stated price target for Health Catalyst Inc (HCAT) is $40, from its action on Mar 4, 2022.
- What is Raymond James's rating on HCAT?
- Raymond James rates HCAT Mkt Perform, a neutral rating, as of May 10, 2023.
- When did Raymond James last change its view on HCAT?
- On May 10, 2023, Raymond James downgrades to Mkt Perform from Outperform.
More HCAT rating histories
All Raymond James ratingsHCAT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.